丹参酮Ⅱ_A磺酸钠对冠心病患者血小板功能的影响  

Effect of Sulfotanshinone Sodium Injection on the Platelet Function in Patients with Coronary Heart Disease

作　　者：杨涓[1] 董江川[2,3] 李大主[3] 王博远[3] 林静[3] 张沛[3] 

机构地区：[1]重庆医科大学附属第一医院中西医结合科,重庆市渝中区友谊路1号400016 [2]重庆医科大学中医药学院临床教研室 [3]华中科技大学同济医学院附属协和医院

出　　处：《中医杂志》2013年第15期1294-1296,共3页Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(81170258)

摘　　要：目的探讨丹参酮ⅡA磺酸钠治疗冠心病的作用机制。方法 89例冠心病患者随机分为治疗组45例和对照组44例。对照组采用阿司匹林、硝酸酯类、他汀类降脂药等常规治疗,治疗组在常规治疗基础上加用丹参酮ⅡA磺酸钠注射液,两组均连续用药7天。于治疗开始前1天及结束次日检测两组血液流变学、纤维蛋白原(Fg)、血小板聚集率(PAG)与血小板膜糖蛋白CD62p、CD63、CD42b及PAC-1水平。结果两组患者治疗后高切全血黏度、低切全血黏度、血浆比黏度、Fg、PAG较治疗前均明显降低,并且治疗组较对照组降低更明显(P<0.05或P<0.01);两组患者治疗后CD62p、CD63、CD42b及PAC-1表达较治疗前均有明显改善(P<0.01),治疗组CD62p、CD63及PAC-1的表达与对照组比较下降更明显(P<0.05或P<0.01)。结论丹参酮ⅡA磺酸钠改善冠心病患者血液流变学,降低血浆Fg水平,抑制血小板聚集,抗血小板活化可能是其治疗冠心病的途径之一。表2两组患者治疗前后CD62p、CD63、PAC-1、CD42b水平比较(%,珚x±s)组别时间例数CD62pPAC-1CD63CD42b对照组治疗前445.91±1.166.58±0.786.27±1.4989.32±15.54治疗后444.06±0.87*5.13±0.86*4.04±1.63*95.28±16.39*治疗组治疗前455.79±1.326.42±0.916.46±1.7290.11±13.47治疗后453.73±1.08*△△4.85±1.14*△3.91±1.58*△97.89±14.76*注:与本组治疗前比较,*P<0.01;与对照组治疗后比较,△P<0.05,△△P<0.013.3不良反应是其治疗CHD的机制之一。Objective To research the effect and mechanism of sulfotanshinone sodium （STS） Injection on patients with coronary heart disease （CHD）. Methods Totally 89 CHD patients were randomized into treatment group of 45 cases and control group of 44 cases. The control group was given conventional treatment of aspirin, nitrates and lipid-lowering statins. The treatment group was added with STS injection. Both groups were administered for 7 continuous days. The blood rheology, fibrinogen （Fg）, platelet aggregation （PAG） and platelet membrane glycoprotein CD62p, CD63, CD42b and PAC-1 were detected one day before treatment and one day after treatment. Results The high-shear whole blood viscosity, low-shear whole blood viscosity, plasma viscosity, Fg and PAG were significantly decreased in both groups after treatment, especially in the treatment group （P0.05 or P0.01）. The expressions of CD62p, CD63, CD42b and PAC-1 were significantly improved in both groups after treatment （P0.01）, especially the expressions of CD62p, CD63 and PAC-1 in the treatment group （P0.05 or P0.01）. Conclusion STS can improve blood rheology, decrease plasma Fg level and inhibit platelet aggregation in CHD patients and anti-platelet activation may be one way to treat CHD.

关 键 词：丹参酮ⅡA磺酸钠 冠心病 血液流变学 血小板聚集 血小板膜糖蛋白 

分 类 号：R259[医药卫生—中西医结合]